ZSAN Zosano Pharma Corp

Zosano Pharma Reports First Quarter 2022 Financial Results

Zosano Pharma Reports First Quarter 2022 Financial Results

FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and statements has been retroactively adjusted to give effect to our April 11, 2022 1-for-35 reverse stock split.

Zosano reported a net loss for the first quarter of 2022 of $33.4 million, or $7.86 per share on a basic and diluted basis, compared with a net loss of $8.1 million, or $2.73 per share on a basic and diluted basis, for the same quarter in 2021.

Research and development expenses for the first quarter of 2022 were $4.5 million, compared with $5.3 million for the same quarter in 2021. The decrease of $0.8 million was primarily due to a decrease of $0.6 million in employee and consulting expenses and $0.3 million in spending for clinical trials, offset by a $0.1 million increase in pre-commercial activities.

General and administrative expenses for the first quarter of 2022 were $2.9 million compared with $2.8 million for the same quarter in 2021. The increase was primarily due to an increase of $0.5 million in professional service fees to our financial and legal advisors and $0.2 million for services related to a special stockholders’ meeting, offset by $0.6 million in lower employee-related expenses.

The impairment loss of $25.9 million for the three months ended March 31, 2022, consists of the write-down of $24.8 million of property and equipment and $1.1 million of right-of-use assets. The impairment loss was primarily related to the write-down of specialized equipment and related manufacturing space for the commercial manufacture of the company’s suspended M207 program.

As of May 11, 2022, the company had approximately $9.9 million of cash and cash equivalents, compared with $13.5 million and $11.0 million as of March 31, 2022 and December 31, 2021, respectively. The company will need substantial additional funding to fund its operations and will not be able to continue as a going concern if it is unable to raise additional funds.

About Zosano Pharma

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on providing rapid administration of approved molecules with established safety and efficacy profiles that may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company’s transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Learn more at .

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits and potential uses of the company’s transdermal microneedle system, statements regarding a need for additional funding in order to continue operations and other future events and expectations described in this press release. Readers are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “scheduled,” “goal,” “approximately” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the company’s ability to continue operations, successfully restructure its indebtedness or complete any strategic transactions and other risks and uncertainties described under the heading “Risk Factors” in the company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, Zosano cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contacts:

Christine Matthews

Chief Financial Officer

510-745-1200

Zosano PR:

Sylvia Wheeler or Alexandra Santos

 or   



ZOSANO PHARMA CORPORATION

CONDENSED BALANCE SHEETS

(in thousands, except par value and share amounts)

 March 31,

2022
 December 31,

2021
 (unaudited)  
ASSETS
Current assets:   
Cash and cash equivalents$13,529  $11,043 
Accounts receivable 91   146 
Prepaid expenses and other current assets 2,012   420 
Total current assets 15,632   11,609 
Restricted cash 455   455 
Property and equipment, net 7,922   32,557 
Operating lease right-of-use assets 2,436   3,769 
Total assets$26,445  $48,390 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:   
Accounts payable$3,720  $2,120 
Accrued compensation 475   1,767 
Build-to-suit obligation, current portion, net of debt issuance costs and discount 1,739   3,822 
Operating lease liabilities, current portion 1,642   1,606 
Other accrued liabilities 2,154   1,818 
Total current liabilities 9,730   11,133 
Build-to-suit obligation, long-term portion, net of debt issuance costs and discount    970 
Operating lease liabilities, long-term portion 2,662   3,081 
Other long-term liabilities    231 
Total liabilities 12,392   15,415 
    
Stockholders’ equity:   
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of March 31, 2022 and December 31, 2021     
Common stock, $0.0001 par value; 250,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 4,902,260 and 3,434,451 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively     
Additional paid-in capital 409,577   395,090 
Accumulated deficit (395,524)  (362,115)
Total stockholders’ equity 14,053   32,975 
Total liabilities and stockholders’ equity$26,445  $48,390 
 
 

ZOSANO PHARMA CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(unaudited)

 Three Months Ended March 31,
  2022   2021 
    
Service revenue$132  $258 
Operating expenses:   
Cost of service revenue 86   162 
Research and development 4,481   5,330 
General and administrative 2,942   2,814 
Impairment loss 25,941    
Total operating expenses 33,450   8,306 
Loss from operations (33,318)  (8,048)
Other income (expense):   
Interest income 2   1 
Interest expense (73)  (97)
Other income (expense), net (20)  2 
Loss before provision for income taxes (33,409)  (8,142)
Provision for income taxes     
Net loss$(33,409) $(8,142)
    
Net loss per common share – basic and diluted$(7.86) $(2.73)
Weighted-average common shares used in computing net loss per common share – basic and diluted 4,248   2,981 



EN
13/05/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zosano Pharma Corp

 PRESS RELEASE

Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11

Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11 FREMONT, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 (“Chapter 11”) of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the company. Zosano continues to operate its business as a “debtor-in-poss...

 PRESS RELEASE

Zosano Pharma Reports First Quarter 2022 Financial Results

Zosano Pharma Reports First Quarter 2022 Financial Results FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and statements has been retroactively adjusted to give effect to our April 11, 2022 1-for-35 reverse stock split. Zosano reported a net loss for the first quarter of 2022 of $33.4 million, or $7.86 per share on a basic and diluted basis, compared wit...

 PRESS RELEASE

Zosano Pharma Provides Corporate Update

Zosano Pharma Provides Corporate Update FREMONT, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the Food and Drug Administration granted Zosano a twelve-month extension to April 20, 2023 to resubmit its M207 New Drug Application. However, in order to preserve its capital and cash resources, Zosano has suspended its M207 program. Additionally, the company’s remaining feasibility study with a pharmaceutical partner is expected to conclude this quarter. Zos...

 PRESS RELEASE

Zosano Pharma Announces Reverse Stock Split Effective Today

Zosano Pharma Announces Reverse Stock Split Effective Today ZSAN common stock expected to begin trading on a split-adjusted basis on April 12, 2022 FREMONT, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company’s common stock. The reverse stock split will become effective today, April 11, 2022. The company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on April 12, 202...

 PRESS RELEASE

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Re...

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results FREMONT, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2021, as well as business updates. “We are in discussions with the FDA to determine if there is a viable option to pursue approval of M207 using the currently available clinical data. In addition, we are actively evaluating financial and strategic alternatives in collaboration with external advi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch